Inovio Pharmaceuticals Inc
F:GBM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Inovio Pharmaceuticals Inc
F:GBM
|
US |
|
E
|
Essex Property Trust Inc
F:EXP
|
US |
|
V
|
Verkkokauppa.com Oyj
F:15V
|
FI |
|
L
|
Loews Corp
F:LTR
|
US |
|
E
|
ExpreS2ion Biotech Holding AB
F:5JD
|
SE |
|
T
|
Taylor Morrison Home Corp
F:THM
|
US |
|
L
|
L'Occitane International SA
XBER:COC
|
LU |
|
L
|
L'Occitane International SA
SWB:COC
|
LU |
|
G
|
GATX Corp
SWB:GAX
|
US |
|
C
|
Cyberark Software Ltd
F:CYB
|
IL |
Wall St Price Targets
GBM Price Targets Summary
Inovio Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
GBM is 3.5085 EUR with a low forecast of 1.5346 EUR and a high forecast of 5.3178 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GBM's stock price target?
Price Target
3.5085
EUR
According to Wall Street analysts, the average 1-year price target for
GBM is 3.5085 EUR with a low forecast of 1.5346 EUR and a high forecast of 5.3178 EUR.
What is the Revenue forecast for Inovio Pharmaceuticals Inc?
Projected CAGR
182%
Over the last 14 years, the compound annual growth rate for Revenue has been -30%. The projected CAGR for the next 8 years is 182%.